Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports

Merck’s deal for Terns sparks debate over a possible biotech bidding war

Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are convinced a better proposal is coming.

Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment

One executive’s patent cliff is another executive’s lucrative exit. German pharmaceutical giant Merck revealed Wednesday that it’s paying $6.7 billion for Terns Pharmaceuticals, as it tries to bridge a multibillion-dollar gap when its bestselling Keytruda comes off patent. Patent Drop The key patent protections on Keytruda, a Spielberg-level blockbuster immunotherapy treatment that outsold all other prescription drugs last year, end in 2028. As …

Merck nears $6 billion acquisition of Terns Pharma to boost cancer portfolio, FT reports

Pharmaceutical company ​Merck is nearing a roughly $6 billion ‌all-cash deal to acquire biotech firm Terns Pharma , the Financial Times reported ​on Tuesday, citing people familiar ​with the matter.

Merck buying Terns in $6.7B deal to bolster its cancer portfolio before key Keytruda patent expires

Merck is buying oncology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion as the pharmaceutical giant works on beefing up its cancer portfolio before a key patent on its cancer drug Keytruda expires in two years.

Merck to buy Terns Pharmaceuticals in $6.7B deal

The deal's centerpiece is a promising leukemia drug, which could help Merck offset the impending decline of Keytruda revenue.

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.